These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12379166)

  • 1. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?
    Fleischmann EH; Schmieder RE
    Curr Cardiol Rep; 2002 Nov; 4(6):474-8. PubMed ID: 12379166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure.
    Derosa G; Maffioli P
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):719-28. PubMed ID: 23750681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta blockers & left ventricular hypertrophy regression.
    George T; Ajit MS; Abraham G
    Indian Heart J; 2010; 62(2):139-42. PubMed ID: 21180305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of left ventricular hypertrophy is a key goal of hypertension management.
    Zhang R; Crump J; Reisin E
    Curr Hypertens Rep; 2003 Aug; 5(4):301-8. PubMed ID: 12844464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options in minimizing left ventricular hypertrophy.
    Devereux RB
    Am Heart J; 2000 Jan; 139(1 Pt 2):S9-14. PubMed ID: 10618582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.
    Morisco C; Argenziano L; Tozzi N; Mele AF; Ricciardelli B; Condorelli G; Trimarco B
    Drugs; 1993; 46 Suppl 2():88-94. PubMed ID: 7512489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
    Krauser DG; Devereux RB
    Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension and left ventricular hypertrophy: is drug therapy beneficial?
    Eselin JA; Carter BL
    Pharmacotherapy; 1994; 14(1):60-88. PubMed ID: 8159603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of left ventricular hypertrophy: are there preferred drugs?
    Diamond JA; Phillips RA
    Curr Hypertens Rep; 2003 Oct; 5(5):368-71. PubMed ID: 12948428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies.
    Fagard RH; Celis H; Thijs L; Wouters S
    Hypertension; 2009 Nov; 54(5):1084-91. PubMed ID: 19770405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of meta-analyses of therapeutic studies on regression of left ventricular hypertrophy.
    Hansson L
    Adv Exp Med Biol; 1997; 432():189-90. PubMed ID: 9433525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and vascular remodelling: effect of antihypertensive agents.
    Mallion JM; Baguet JP; Siche JP; Tremel F; De Gaudemaris R
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S35-41; discussion S49-50. PubMed ID: 10076919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.